Maravai Lifesciences Holdings, Inc.
MRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001823239
No open-market purchases or sales by Maravai Lifesciences Holdings, Inc. insiders were filed in the last 90 days; 177 institutions reported holding it in 13F filings for Q2 2026, worth $898.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Maravai Lifesciences Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Maravai Lifesciences Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Brust Bernd | Chief Executive Officer | 1,561,249 | Sep 9, 2026 | 6 |
| Asarpota Rajesh | Chief Financial Officer | 423,486 | Sep 1, 2026 | 3 |
| Lucier Gregory T | Director | 156,077Indirect | Jun 10, 2026 | 3 |
| Oreshack Kurt | General Counsel | 335,767 | Jun 10, 2026 | 4 |
| Eckert R Andrew | Director | 412,183 | May 28, 2026 | 1 |
| Mihas Constantine S | Director | 184,348 | May 28, 2026 | 1 |
| DeFord John A | Director | 205,478 | May 28, 2026 | 1 |
| Cunningham Sean Laurence | Director | 184,348 | May 28, 2026 | 1 |
| Marker Luke Joseph | Director | 184,348 | May 28, 2026 | 1 |
| Gray Susannah | Director | 216,200 | May 28, 2026 | 1 |
| Dolan Christine | See Remarks | 425,318 | May 22, 2026 | 4 |
| Leddy Peter Michael | See Remarks | 727,177 | Jul 16, 2025 | 0 |
| Hopfield Jessica | Director | 199,907 | Jun 18, 2025 | 0 |
| Daverman Benjamin James | Director | 138,055 | Jun 18, 2025 | 0 |
| Prahalad Murali | Director | 154,607 | Jun 18, 2025 | 0 |
| Herde Kevin | Chief Financial Officer | 674,636 | May 28, 2025 | 0 |
| Martin William E. III | Chief Executive Officer | 1,814,643 | Mar 19, 2025 | 0 |
| Buzzeo Rebecca | See Remarks | 606,791 | Mar 19, 2025 | 0 |
| Burch Andrew | See Remarks | 369,183 | Jan 17, 2025 | 0 |
| Hull Carl | See Remarks | 175,000Indirect | Nov 12, 2024 | 0 |
| GTCR Co-Invest XI LP | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| GTCR Fund XI/B LP | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| GTCR Fund XI/C LP | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| GTCR Partners XI/B LP | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| GTCR Investment XI LLC | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| GTCR Partners XI/A&C LP | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| Maravai Life Sciences Holdings 2, LLC | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| Maravai Life Sciences Holdings, LLC | Director, 10% Owner | 20,150,005Indirect | May 30, 2024 | 0 |
| Ashkenazi Anat | Director | 60,768 | May 24, 2024 | 0 |
| Neel Brian | See Remarks | 16,473 | Feb 17, 2023 | 0 |
| Hance Robert B | Director | 26,123 | Nov 23, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 (view filing) | Jun 9-10 | 1 day | Oreshack KurtGeneral Counsel | SSaleClass A Common Stock | −50.0K | $5.08 | −$254.0K | −13.0%335.8K after | 2 lots10b5-1 |
| Dec 9, 2025 (view filing) | Dec 5-8 | 4 days | Lucier Gregory TDirector | PPurchaseClass A Common Stock | +100.0K | $3.69 | +$368.5K | +181.4%155.1K after | 2 lots |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Brust BerndChief Executive Officer | PPurchaseClass A Common Stock | +216.2K | $3.25 | +$702.7K | +86.3%466.8K after | |
| Nov 13, 2025 (view filing) | Nov 11-12 | 2 days | Brust BerndChief Executive Officer | PPurchaseClass A Common Stock | +250.6K | $3.23 | +$809.0K | New position250.6K after | 2 lots |
| Jan 31, 2025 (view filing) | Jan 31 | Same day | Oreshack KurtGeneral Counsel | SSaleClass A Common Stock | −25.0K | $5.03 | −$125.8K | −13.0%167.6K after | 10b5-1 |
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | DeFord John ADirector | PPurchaseClass A Common Stock | +17.5K | $5.75 | +$100.6K | +33.3%70.0K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Hull CarlSee Remarks | PPurchaseClass A Common Stock | +175.0K | $5.64 | +$987.0K | New position175.0K after | |
| May 30, 2024 (view filing)5:39 PM ET | May 28 | 2 days | GTCR Co-Invest XI LP and 7 othersDirector, 10% Owner | SSaleClass A common stock | −9.94M | $9.82 | −$97.6M | −33.0%20.2M after |